Thymosin Alpha 1 Trial Aims to Prevent Organ Failure After Aortic Dissection Surgery

Acute type A aortic dissection (ATAAD) is a life-threatening cardiovascular emergency requiring urgent surgical repair, often leading to severe complications like systemic inflammatory response syndrome (SIRS) and postoperative organ dysfunction. Current standard care effectively addresses the dissection but often falls short in mitigating the subsequent immune imbalance and its detrimental effects on organ function. This trial protocol aims to evaluate if thymosin alpha 1 (Tα1) supplementation can prevent SIRS-mediated organ injury and improve long-term outcomes in these high-risk patients.

As this is a trial protocol, specific results are not yet available, but the study is designed to identify a significant therapeutic effect. The primary objective is to determine if thymosin alpha 1 (Tα1) can significantly reduce postoperative organ dysfunction in patients after ATAAD surgery. Researchers will compare the mean Sequential Organ Failure Assessment (SOFA) scores between the Tα1 group and the placebo group, with daily measurements starting from postoperative day 7. A statistically significant reduction in SOFA scores in the Tα1 group would indicate improved organ function and reduced systemic inflammatory response syndrome (SIRS). If successful, this trial aims to demonstrate a quantitative improvement in patient outcomes. The most important finding, if successful, would be a statistically significant reduction in mean postoperative SOFA scores in patients receiving Tα1 compared to the placebo group, indicating a novel therapeutic approach to mitigate organ injury.